SecBot SecBot

SPRO

Spero Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001701108 Biotech & Drug Discovery
$0.9460 −0.05 (−5.40%)
Nov 16 4:00 PM ET · prev $1.00
Market cap
$58.3M
Micro cap
Consensus
Buy
78% Buy or better · 9 analysts
Median target
$6.00
+534% · range $4.00–6.00
1 year
−61.1%
from $2.43 · Nov 17
30 days
−15.5%
from $1.12
52-week range
$0.9460–2.98
at the low
Avg volume 20D
355.2K
shares / day
Short interest
787.0K
≈1.4% of shares · −6.4%
Days to cover
2.2
at average volume
Insider net
−$499.1K
0 buyers · 2 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
13
analyzed by SecBot
SecBot read BEARISH 7 reports · 90 days
Balance 3 bearish · 0 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 7/7

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    2 insiders sold $499.1K.

  • InstitutionsMIXED

    Q3 2026: 7 added (0 new), 7 trimmed or exited.

  • AnalystsBULLISH

    7 of 9 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest −6.4% to 787.0K shares. 2.2 days to cover, ≈1.4% of shares.

  • TrendDOWNTREND

    16% below its 50-day average. New closing low $0.9460 on Nov 16.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
RENAISSANCE TECHNOLOGIES LLCADD1,409,783$1.7M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPDOUBLED997,123$1.2M
RAYMOND JAMES FINANCIAL INCADD755,633$914.3K
MORGAN STANLEYDOUBLED258,645$313.0K
Invesco Ltd.DOUBLED165,530$200.3K
DIMENSIONAL FUND ADVISORS LPTRIM91,287$110.4K
SIMPLEX TRADING, LLCTRIM36,830$44.6K
JANE STREET GROUP, LLCNEAR_EXIT20,185$24.4K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

9 analysts
Buy 78% rate it Buy or better
Strong Buy2Buy5Hold2Sell0Strong Sell0
12-month targets · 3 analysts

Price is below the lowest target. Median implies +534%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Oct 28, 2026Cantor Fitzgerald
INITIATE
INITIATEOverweight
Sep 14, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$499.1K
sold · 2 insiders
DateInsiderTypeValue
Nov 10, 2026
HO WILLIAM
Director
Nov 10, 2026
AWARD100,000 sh
Nov 9, 2026
Rajavelu Esther
See Remarks
Nov 9, 2026
SELL$42.5K
Aug 3, 2026
Zack Debra
Chief Medical Officer
Aug 3, 2026
AWARD324,675 sh
Aug 3, 2026
Zack Debra
Chief Medical Officer
Aug 3, 2026
AWARD162,311 sh
Jun 23, 2026
Pottage John C Jr
Director
Jun 23, 2026
AWARD10,000 sh
Jun 23, 2026
Jackson Scott Thomas
Director
Jun 23, 2026
AWARD10,000 sh
Jun 23, 2026
Pottage John C Jr
Director
Jun 23, 2026
AWARD20,000 sh
Jun 23, 2026
Jackson Scott Thomas
Director
Jun 23, 2026
AWARD20,000 sh

Earnings setup

Estimates
−$0.23
EPS estimate, this quarter
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.23-$0.23–-$0.23No data$0.00
Next Q-$0.23-$0.23–-$0.23No data$0.00
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
787,025
shares short
-6.4%
vs prior settlement
2.2
days to cover
≈1.4%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 12, 2026 SEC
Spero Therapeutics reported Q3 2026 results with no revenue and a net loss of $44.3 million ($0.76 per share)…
8-K · Impact 4/10
Nov 12, 2026 Earnings result
SPRO Q3 2026 Earnings: EPS $-0.16 (+66.6% vs est)
Nov 10, 2026 SEC
William Ho, M.D., Ph.D., filed a Form 3 initial statement of beneficial ownership with Spero Therapeutics, Inc…
3 · Impact 2/10
Nov 10, 2026 SEC
Spero Therapeutics disclosed the resignation of director Patrick Vink, M.D., effective November 10, 2026, and the…
8-K · Impact 2/10
Nov 10, 2026 Insider
HO WILLIAM was granted 100,000 shares
Director
Nov 9, 2026 Insider
Rajavelu Esther sold 40,851 shares
See Remarks @ $1.04 ($42.5K)
Sep 30, 2026 Inst.
RENAISSANCE TECHNOLOGIES LLC · ADD
1,409,783 shares ($1.7M)
Sep 30, 2026 Inst.
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP · DOUBLED
997,123 shares ($1.2M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Recent
Nov 12, 2026
Earnings result
SPRO Q3 2026 Earnings: EPS $-0.16 (+66.6% vs est)
Nov 4, 2026
Press release
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on…
Nov 2, 2026
Press release
Spero Therapeutics to Present at Investor Conferences in November
CAMBRIDGE, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on…
Oct 15, 2026
Press release
Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on...
Oct 2, 2026
Press release
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on…

SecBot reports

13 filings · 4 press releases · 2 bullish · 3 bearish · 1 mixed · 7 neutral
All SPRO filing & press-release reports (17)